Streetwise Reports' Article Archives — Current Month (9)
Cleantech Firm Expands Breakthrough Wound Solution to Veterans (09/10/2026)
BioLargo Inc. (BLGO:OTCQX) is bringing its FDA-cleared ViaCLYR wound solution to U.S. government and VA-contracted healthcare facilities through a new deal with Spartan Medical.
Chart Buy Signals After Co. Targeting U.S. Alzheimer's Market Reports Final Major Regulatory Milestone (09/10/2026)
Technical Analyst Stewart Thomson reviews Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW0:FRA) following its achievement of a major regulatory milestone.
BioLargo Subsidiary Secures Spartan Medical Deal for ViaCLYR Government Sales (09/10/2026)
BioLargo subsidiary Clyra enters an exclusive reseller agreement with Spartan Medical for ViaCLYR wound care solution targeting U.S. government facilities and ECAT listing amid expanding wound care demand.
Sernova-Seraxis Merger to Create BetaNova with US$10M for T1D Islet Trial (09/09/2026)
Sernova and Seraxis have entered into a definitive agreement to merge and create BetaNova Biotherapeutics, with US$10 million in financing to advance stem cell-derived islet therapy for type 1 diabetes, targeting Phase 1/2 data by mid-2027.
Biotechs Combine to Target Type 1 Diabetes Treatment (09/08/2026)
Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) has agreed to merge with privately held Seraxis to form BetaNova Biotherapeutics, a U.S.-based company advancing cell therapies for type 1 diabetes. Find out why one analyst calls the combination a good strategic move.
AI Cancer Drug Pipeline Advances as 72% of Budget Shifts to Drug Discovery (09/03/2026)
Rakovina Therapeutics Inc. (RKV:TSX.V) cut its Q2 net loss 41% year over year while advancing three AI-powered cancer drug programs and closing a CA$1.99 million non-brokered private placement after quarter-end.
Digital Health Platform Sees US Patient Visits Surge 196% and Quarterly YoY Revenue Jumps 43% (09/03/2026)
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported Q2 revenue of US$734,028 as U.S. patient visits nearly tripled and its in-network coverage expanded to approximately 24 million lives.
Rakovina Therapeutics Shifts 72% of Budget to AI Cancer Programs (09/03/2026)
Rakovina Therapeutics allocated 72% of its budget to AI-powered drug discovery in the second quarter of 2026, up from 57% in Q2 2025. See the three AI-supported DDR programs and upcoming milestones for retail investors.
Telehealth Platform Delivers 196% U.S. Visit Growth in Q2 (09/03/2026)
Rocket Doctor AI reports 43% revenue growth and 196% U.S. patient visit increase in Q2 2026, backed by 24 million covered lives and an expanding payer network.
More Archives
2026Aug Jul Jun May Apr Mar Feb Jan
2025Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
